Biomarkers /

PDS5B

Back to Biomarkers List
Associated Genetic Biomarkers
Associated Diseases

Overview

Location [1]
13q13.1
Protein [2]
Sister chromatid cohesion protein PDS5 homolog B
Synonyms [1]
APRIN, AS3, CG008

PDS5B is altered in 0.69% of all cancers with diffuse large B-cell lymphoma, not otherwise specified, B-cell lymphoblastic leukemia/lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, and follicular lymphoma having the greatest prevalence of alterations [3].

PDS5B GENIE Cases - Top Diseases

The most common alterations in PDS5B are PDS5B Mutation (0.33%), PDS5B Loss (0.19%), PDS5B A1038T (0.02%), PDS5B Amplification (0.02%), and PDS5B D1002G (0.02%) [3].

PDS5B GENIE Cases - Top Alterations

Clinical Trials

View Clinical Trials for PDS5B

Significance of PDS5B in Diseases

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.